Introduction
A standardized approach to the evaluation of the man with Peyronie's disease does not exist. An internationally agreed upon protocol would be invaluable in this field as this would provide a uniform assessment of men with Peyronie's disease and aid in interpreting outcomes from clinical trials. It is the goal of this article to present concepts which will lead to the development of such an assessment. We will also review the subjective and objective measures currently employed in describing the penile manifestations of Peyronie's disease, as well as discussing a questionnaire focusing on Peyronie's disease which is in development and will be validated in a forthcoming multicenter study.
In general, the initial evaluation should focus on clinical parameters which are important to the physician, patient and/or investigator. These would include approximate onset of Peyronie's disease, precipitating event (if known), penile deformity, erectile capacity (ie, rigidity) and overall subjective level of sexual ability. Additional questions would investigate the impact and distress caused by Peyronie's disease upon intrapersonal perception of sexual function, as well as interpersonal relationships. The challenge is to assemble a protocol which will be reproducible, reliable and universally acceptable. Unfortunately, there have been no studies upon which to build that have tried to determine what are the important parameters pertaining to Peyronie's disease. This is an especially difficult task as there is already lack of agreement in the literature as to how to objectively measure the most important parameter, that being penile angulation.
The following is a discussion of a recommended algorithm for the initial evaluation of men with Peyronie's disease including demographic data, physical findings, objective measures of penile deformity, assessment of erectile function as well as subsequent review of the important measures of change occurring as a result of treatment. This will be followed by a brief summary of the findings of a recent survey of the published literature on medical and surgical therapy of Peyronie's disease. The goal of this survey was to provide insight as to the parameters currently used by investigators. Finally, we will review the important parameters to be evaluated in the man undergoing treatment for Peyronie's disease and how best to evaluate and report on them today.
The initial evaluation starts with a history which should provide information regarding the duration of disease, any recognized triggering event, as well as the presenting signs and symptoms of Peyronie's disease most frequently being penile pain, lump/ nodule and curvature. A detailed medical and sexual history is recommended. This can be accomplished using a standardized medical questionnaire (Appendix A), and sexual function may be further assessed using the International Index of Erectile Function (IIEF). 1 This readily available and validated questionnaire is recommended to be used at baseline and again following treatment. The Peyronie's Disease Index (PDI) questionnaire will allow assessment of many sexual function characteristics. It is in development with validation in progress and will be discussed later. 2 The medical history should contain questions allowing identification of erectile dysfunction (ED) risk factors. In addition, prior therapy for Peyronie's disease should be noted and whether any benefit occurred. The patients' estimated curvature both in terms of degree and direction should be documented. A baseline subjective evaluation of the patient's rigidity may be graded using a numerical scale (ie, 0-4, 0-10). In addition, a useful question, the answer to which may provide further information regarding the adequacy of the patient's penile rigidity for coitus, is 'Imagine that your penis has no deformity. Do you feel that the rigidity that you currently obtain with sexual stimulation would be adequate for vaginal penetration and completion of sexual intercourse?' Other deformities should be assessed including the presence of narrowing, indentation, hinging of the shaft, distal softening and penile shortening. Shortening should be specifically documented as to its presence and the patient's estimate of length loss.
The next segment of the evaluation is the physical exam which would begin with a routine genitourinary exam, as well as evaluation of the hands and feet for evidence of Dupuytren's contracture or Ledderhose scarring of the plantar fascia, respectively. These may be indications of a systemic fibromatosis disorder. The penile exam is clearly critical starting with measurement of penile stretched length. This will be discussed further in a later part of this article. Plaque characteristics should be noted in terms of location, size, tenderness to palpation and texture (ie calcification). Laboratory studies can be kept to a minimum and may include, depending upon indication, testosterone, PSA, lipid panel and serum glucose assessment.
Objective evaluation of deformity is recommended to include routine penile duplex ultrasound with pharmacological stimulation with either a vasoactive injection or oral sildenafil citrate to induce a maximum erection similar to or better than that which the patient would experience when sexually aroused. The goal here is to be able to obtain an objective measure of vascular flow parameters during development of erection, assess plaque characteristics including approximate size, location and calcification, erectile response which should be graded independently by the ultrasound technician or physician. Curvature at the point of maximum erection is best measured directly by protractor and is in our opinion the most consistent and reliable technique. Girth-related changes are most commonly recorded as reported subjectively by the patient. A photograph performed by the technician and/or brought in by the patient is at significant risk for error and inconsistency and is not recommended. 2 It is the first questionnaire addressing multiple important parameters for the patient with Peyronie's disease. To date 35 questions have been proposed. The ongoing evaluation of this index includes testing criteria of its validity by examining the PDI's correlation to physical examination findings, evaluating convergent and divergent predicted validity via several established questionnaires of sexual function including the Derogatis Interview for Sexual Functioning (DISF), the Short Marital Adjustment and Prediction Test and the Social Desirability Scale. [4] [5] [6] In addition, confirmatory factor analysis is being performed to provide evidence of the constructed domains of the questionnaire. Reliability and stability testing will be accomplished by repeating the questionnaire in each tested individual after 4 weeks. The PDI evaluation process will be conducted in a multicenter IRB approved study.
As a brief review, the PDI starts with a definition of descriptive terms including curvature, hourglass deformity, sexual activity, intercourse and stimulation. This is most useful as there can be confusion with respect to the patient's understanding of these concepts. At this time, girth-related changes in particular hourglass, indentation and hinge effect are not noted and may be included. The domains of the PDI include deformity, pain, impact, distress, desire and satisfaction. Question design follows the IIEF format loosely and includes patient assessment of curvature direction and severity by degree and employs a useful visual scale. Hourglass deformity is questioned but there is no visual scale. Shape assessment is in progress with regard to indentation, hourglass, buckling and hinge effect. A series of questions follows which relate to specific items in terms of both frequency and degree which will provide detailed information from the patient. This determination of frequency and degree is assessed by questions pertaining to the (a) affect of curvature on intromission, (b) pain with erection affecting penetration and separately maintaining erection, (c) ability to obtain and separately maintain erection to completion of intercourse and to orgasm, (d) distress with deformity, (e) confidence in obtaining and separately maintaining erection and lastly sexual satisfaction.
Given that there is no currently accepted standard approach to the evaluation of the man with Peyronie's disease nor any previously published analysis of existing approaches, a survey was performed by the authors of this article. The goal of this study was to query the reporting on men with Peyronie's disease in the published literature. The review process included evaluation of a database of 68 articles in the peer-reviewed literature on the medical and surgical treatment of Peyronie's disease published in English over the past 10 years. A total of 85 separate items were examined and recorded in spread sheet fashion as to the presence or absence of these items includingFbaseline demographics, clinical characteristics, physical findings, study design (placebo control, etc), subjective/objective measures of deformity, method of measurement of deformity, post-treatment outcome results, adverse events and patient satisfaction ( Table 1) .
The results of this survey revealed several important factors. Deformity was measured objectively with respect to curvature in only 38% of articles and specifically by 'eyeball estimate' in 7%, photograph 7%, protractor 6% and nonspecified 18%. Improvement measures were not reported in a consistent or routine fashion. For example, change in curvature by degree was reported in only 9% of articles and by percent of patients experiencing any change in only 3%. Penile length change was reported subjectively in 13% of the articles versus objectively measured in 9%. Change in erectile capacity was reported in 43% of articles based upon subjective reports and in only 12% following objective measurement, most commonly following penile duplex ultrasound. Patient satisfaction with the therapy was subjectively reported in 28% of articles. Only 6% of articles used any form of validated questionnaire (eg, IIEF, EDITS). 7 Although this type of survey is incomplete, and may fail scientific scrutiny, the results are certainly emblematic of the problem that we face in terms of making sense of the available published literature.
The question remains as to what are the important measures that must be documented particularly for men entering clinical trials or who have undergone medical or surgical therapy which are intended to be reported in the medical literature, and how should these measures be performed to obtain the most accurate and reproducible results. The first and in our opinion the most important measure is curvature. The assessment of curvature has been measured by a variety of techniques and is most prone to subjective interpretation and inaccuracies. Subjective reporting by the patient allows an estimate of curvature which is important to document, but there can be significant variance between the patient's estimate and objective measures of curvature.
It is our opinion that all of the proposed objective techniques to measure penile angulation are subject to inaccuracies as a result of variability in penile rigidity at the time of measurement. But, it appears today that protractor assessment of the angulation at the time of maximum erection by a technician/ physician will be the most reliable approach. Photographing the erect penis by the patient or physician and then measuring angulation has already been suggested to be inaccurate based on multiple parameters and the potential for numerable inconsistencies. 'Eyeball' estimate certainly is no better than a guess. Vacuum-induced erection has been employed. 8 Unfortunately, personal experience with this technique suggests that curvature is not at all accurately assessed as the erection obtained is not consistent with the patient's erection. This is because the enhanced size of the penis obtained by vacuum is made up of both intra and extracorporal components, 9 the latter of which masks shaft deformity and usually makes the penis seem straighter than it is when stimulated sexually or pharmacologically.
Shaft narrowing deformity measurements also appear to be important, but can it be measured reliably? In the articles reviewed recently, when girth or narrowing abnormalities were reported it was always as described by the patient, if it was reported at all. There is no validated objective measure of change in girth. Several techniques may be considered including measuring erect shaft circumference with a string or flexible ruler at the points of maximum versus minimal deformity. A photograph may also be used to measure the diameter of the penis at different points along the shaft, but this suffers from inaccuracy and difficulty with interpretation.
Plaque size has been commonly reported in the literature as a parameter of successful treatment. Is a change in plaque size important? It is our opinion that it is not, as a change in plaque size has not been found to be a reliable indicator of improvement of any other functional deformity. 10 Is change in plaque size measurable? It appears that this cannot be done accurately or reproducibly by any technique. This is because the typical plaque is not a simple discrete finding. It may have extensions proximally, distally, laterally and through the septum. In addition, it is not uniform in thickness. Therefore, which dimensions should be measured, length, width and/or depth? How should it be measured? Estimating size, that is, length and width, for instance, by eye seems to have little value, whereas with calipers and/or ruler is likely the best technique, as ultrasound and MRI adds expense with little value. Ultimately overall change in plaque size following treatment is interesting, but appears to be of little clinical significance.
Is measurement of erectile capacity (ie, rigidity) important? Yes, this appears to be one of the most important issues for the patient. Most commonly, this is reported subjectively by the patient during exit interviews following treatment. It would seem that erectile capacity and rigidity would be best evaluated by validated questionnaires such as the IIEF and the PDI. Objective measurements, if indicated, may include a duplex ultrasound, vasoactive penile injection alone without imaging. Nocturnal penile tumescence and rigidity (NPTR) monitoring and cavernosometry, have limited value in telling us the ridigity of the patient's sexually induced erection.
As to changes in penile length, is this important? For many men, this may be the most important change. But is it measurable? At this point there is no uniform approach. Multiple techniques have been described. These involve placing the penis on stretch and measuring from the skin at the base of the penis dorsally to the meatus. It is our recommendation that this length be obtained by pressing down on the fatpad to the pubis and measuring dorsally on full stretch to the corona with a centimeter ruler. Here, the variability of fat/skin interfering with length measures is lessened proximally and the corona is a reliable fixed point distally. Measuring length in the erect state is wrought with difficulty in reproducibility and the technique of measuring the difference between dorsal and ventral length from base to corona is also difficult to reproduce.
To summarize, it appears the most important feature with respect to reporting on outcomes in studies of men undergoing therapy for Peyronie's disease is curvature change. When reporting on curvature, this should include degree measured in each individual (as a mean with range for the group) and overall percentage of men experiencing a changeFbetter, worse, unchanged. On the other hand, the percent change of curvature seems of limited value as it does not really reflect a meaningful result. For example, in the case where a large percentage change is reported, this may not reflect a significant degree change (eg, a 50% reduction in a 201 curve is not the same as a 50% reduction of a 90% curve). Clearly, change in curvature must be compared to baseline measures in all dimensions, it is our recommendation that the sum of the changes be reported. This would be pertinent in the situation where for instance there was both lateral and dorsal curvature, and where change occurred in one or both dimensions, the reported change in this case should be the sum of the degree changes. An acceptable and reliable method to measure girth changes has not been established. At this point, reporting on subjective change in girth and axial stability are worthwhile until an agreed upon method for measuring this parameter is established. Length change needs to be measured as this is an important issue for patients particularly following surgery, and therefore, a consistent technique must be used. We recommend that the stretched penile length technique of measuring from pubis by compressing the fatpad to the dorsal corona is a reliable method. The ability to obtain and maintain erections for satisfactory sexual performance is also important and is ultimately based upon subjective reporting, but may be best measured and reported upon using an IIEF-type questionnaire or the Peyronie's Disease Index which is in development. Lastly, a measure of patient satisfaction is indicated, as the physician's perception of outcome may not correlate with that of the patient. Our suggested approach here would be a validated instrument such as the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) or the Peyronie's Disease Index. 2, 7 It is clear that for us to make progress in the field of Peyronie's disease with respect to treatment assessment, the development of a standardized and globally accepted evaluation algorithm is in order. There is strong agreement by experts in this field that it is time for such an evaluation approach.
Currently, it appears that the evaluation and treatment outcome assessment of the man with Peyronie's disease is intuitive, but it is time to establish consistency within the literature. A proposed patient/physician intake questionnaire with attention to initial presentation, medical and pertinent sexual history, physical findings and duplex ultrasound report is found in Appendix A.
